- Home
- TNON vs LGVN Comparison
TNON vs LGVN Comparison
Compare TNON & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNON | LGVN |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 12.2M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TNON | LGVN |
|---|---|---|
| Price | $0.98 | $0.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $6.50 |
| AVG Volume (30 Days) | 77.5K | ★ 300.8K |
| Earning Date | 11-13-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,233,000.00 | $1,437,000.00 |
| Revenue This Year | $19.56 | N/A |
| Revenue Next Year | $71.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.85 | $0.49 |
| 52 Week High | $5.85 | $1.92 |
Technical Indicators
Market Signals| Indicator | TNON | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 44.07 |
| Support Level | $0.94 | $0.52 |
| Resistance Level | $1.03 | $0.60 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 39.07 | 42.57 |
Price Performance
Historical ComparisonAbout TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.